Equities Research Analysts’ updated eps estimates for Friday, September 8th:
AllianceBernstein Holding L.P. (NYSE:AB) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $26.00 target price on the stock. According to Zacks, “ALLIANCE CAP MANAGEMENT L.P. provides diversified investment management services, primarily to pension funds, endowments, foreign financial institutions, and to individual investors. “
Adva Optical Netwo (NASDAQ:ADVOF) was downgraded by analysts at Zacks Investment Research from a buy rating to a sell rating. According to Zacks, “ADVA Optical Networking SE develops, manufactures and sells optical and Ethernetbased networking solutions. It serves telecommunications service providers, private companies, universities and government agencies. ADVA Optical Networking SE is headquartered in Munich, Germany. “
Alstom ADR (OTCMKTS:ALSMY) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $4.00 price target on the stock. According to Zacks, “Alstom SA develops and markets systems, equipment and services for the railway sector. Its product includes bogies, traction systems, electrification, track laying and urban integrated solution. It also offers services such as parts and repairs, maintenance, customisation, modernisation and support services. Alstom SA is headquartered in France. “
Absolute Software (NASDAQ:ALSWF) was downgraded by analysts at Zacks Investment Research from a buy rating to a hold rating. According to Zacks, “Absolute Software Corporation engages in the business of providing firmware-persistent endpoint security and management solutions. It provides solutions for computer security monitoring and endpoint management industry. The company’s solutions include data protection, lifecycle management, enterprise mobility management and IT service management as well as data loss prevention. Absolute Software Corporation is headquartered in Vancouver, Canada. “
ArQule (NASDAQ:ARQL) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $1.25 target price on the stock. According to Zacks, “ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company’s targeted, broad-spectrum products and research programs are focused on key biological processes that are central to cancer. ArQule’s lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy. The Cancer Survival Protein modulation platform has generated a clinical-stage product that mediates its effects by inhibiting the activity of a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company’s lead ACT program, based on the E2F-1 pathway, is partnered with Roche. “
Array BioPharma (NASDAQ:ARRY) had its buy rating reaffirmed by analysts at Cantor Fitzgerald. They currently have a $13.00 target price on the stock. The analysts wrote, “ARRY’s e-poster presentation of the safety lead in for the Phase III BEACON CRC study suggests that binimetinib/encorafenib could expand its market potential to colorectal cancer, which the shares do not currently reflect, in our view.””
Banco Bilbao Vizcaya Argentaria SA (NASDAQ:BBVA) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. The firm currently has $9.75 price target on the stock. According to Zacks, “Banco Bilbao Vizcaya is engaged in a wide variety of banking, financial and related activities in Spain. “
Biohaven Pharmaceutical Holding Co (NASDAQ:BHVN) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “
Burberry Group Spon (OTC:BURBY) was upgraded by analysts at Credit Suisse Group from a neutral rating to an outperform rating.
Mylan N.V. (NASDAQ:MYL) had its hold rating reissued by analysts at Cantor Fitzgerald. The firm currently has a $34.00 target price on the stock.
NewLink Genetics Corporation (NASDAQ:NLNK) was upgraded by analysts at Robert W. Baird from a neutral rating to an outperform rating. Robert W. Baird currently has $22.00 target price on the stock, up from their previous target price of $8.00.
PEUGEOT SA EUR1 (OTC:PEUGF) was downgraded by analysts at BNP Paribas from a neutral rating to an underperform rating.
BMO Capital Markets initiated coverage on shares of Tmx Group (NASDAQ:TMXXF). They issued a market perform rating on the stock.
Select Energy Services (NASDAQ:WTTR) had its buy rating reissued by analysts at FBR & Co.
